Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Invested Capital (2017 - 2025)

Historic Return on Invested Capital for Karyopharm Therapeutics (KPTI) over the last 9 years, with Q4 2025 value amounting to 0.34%.

  • Karyopharm Therapeutics' Return on Invested Capital fell 3500.0% to 0.34% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.34%, marking a year-over-year decrease of 3500.0%. This contributed to the annual value of 0.4% for FY2025, which is 3500.0% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Return on Invested Capital of 0.34% as of Q4 2025, which was down 3500.0% from 0.43% recorded in Q3 2025.
  • Karyopharm Therapeutics' 5-year Return on Invested Capital high stood at 4.49% for Q1 2023, and its period low was 32.5% during Q1 2021.
  • Its 5-year average for Return on Invested Capital is 0.42%, with a median of 0.87% in 2024.
  • Per our database at Business Quant, Karyopharm Therapeutics' Return on Invested Capital tumbled by -309100bps in 2021 and then skyrocketed by 334900bps in 2022.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Return on Invested Capital stood at 0.96% in 2021, then skyrocketed by 90bps to 1.82% in 2022, then plummeted by -40bps to 1.1% in 2023, then plummeted by -37bps to 0.69% in 2024, then plummeted by -50bps to 0.34% in 2025.
  • Its last three reported values are 0.34% in Q4 2025, 0.43% for Q3 2025, and 0.53% during Q2 2025.